Viewing the development of the industry from the 2019 report card of pharmaceutical machine enterprises

Pharmaceutical Network Market Analysis: Since February, Canaan Technology, Chutian Technology and other pharmaceutical equipment enterprises have released the 2019 performance report card, on the overall performance situation, in 2019, pharmaceutical machine enterpriseperformance to good, some enterprises channel layout results, there are breakthroughs and challengesPharmaceutical equipment (source: Pharmaceutical Network) a number of enterprises released a report card on February 29, Chiyyama machine recently released the 2019 annual results bulletin, 2019 is expected to lose 723 million yuan - 718 million yuan, a loss of 2,466 million yuan in the same period last year
On February 29, Chutian Technology recently announced its 2019 annual results, with total operating income of RMB1,916 million in 2019, up 17.45% yoy, and net profit attributable to shareholders of listed companies was RMB48.5517 million, up 17.52% from a year earlier
February 28 news, Canaan Technology recently released the 2019 annual results of the announcement, 2019 the company achieved total operating income of 717 million yuan, an increase of 23.91 percent from a year earlier;
February 28 news, Tailin Bio recently announced the 2019 annual results of the announcement, 2019 total operating income of 183 million yuan, an increase of 14.81 percent over the same period last year, the net profit attributable to shareholders of listed companies was 3661.00 million yuan, a decrease of 24.07 percent over the same period last year
On February 27, Dongfulong recently announced its 2019 annual results, with total operating income of 2,275 million yuan in 2019, up 18.70 percent from a year earlier, and net profit attributable to shareholders of listed companies of 143 million yuan, up 103.53 percent from a year earlier
Xinlai Yingshi also recently announced its 2019 annual results, with total operating income of RMB1,379 million in 2019, up 17.41% yoy, and net profit attributable to shareholders of listed companies was RMB64.8555 million, up 67.90% from a year earlier
As can be seen, the net profit of the five pharmaceutical machine companies increased by three from a year earlier, and two of them grew by more than 50%Overall, the results of pharmaceutical machine enterprises in 2019 are doing well
Industry development summary On the above-mentioned pharmaceutical machine enterprise report, in 2019, many pharmaceutical equipment enterprises actively explore the development model, including upgrading towards the overall solution, increase disinvestment in research and development, layout of the large health industry strategy, to promote the pharmaceutical equipment industry towards high-quality direction
For example, Dongfulong in the reporting period to implement the "systematic, international, digital" development strategy, to actively explore the market, internal business integration and fine management, cost control is beginning to bear fruit
Unusually, during the reporting period, Chutian continued to provide the overall solution of medical equipment, pharmaceutical plant project general contracting (EPC) and pharmaceutical wisdom factory deep-cultivation, in the hands of sufficient orders, the company achieved operating income of 1.9 billion yuan, an increase of 17.45% over the previous yearAt the same time, the company further increased investment in research and development to strengthen core competitiveness, in addition, the company to strengthen internal control management, combing and optimizing business processes, improve the efficiency of the company's management, the company's profitability level has improved from the previous year
Canaan Technology also actively promoted endogenous growth and extended development during the reporting period, and gradually implemented the "solid formulation intelligent factory overall solution provider" and the strategic layout of the large health industryAt the same time, the company continues to increase the development of new markets and new products research and development investment, strengthen brand effect and marketing network channel construction, continue to promote collaborative management and quality enhancement work;
However, with the increasingly fierce competition in the pharmaceutical equipment industry, many pharmaceutical companies in 2019 to increase investment in research and development, so that the company's costs rise, the pressure appears
For example, Tailin Bio's revenue increased compared with the same period last year, but the total profit and net profit attributable to shareholders of listed companies decreased compared with the same period last year, mainly due to: the company's business is carried out steadily, sales revenue continued to grow, but the country's major special research and development investment and new production base put into use and other factors also led to increased operating costs and costs.